```html

Zollinger‑Ellison Ulcer

Overview

Zollinger‑Ellison ulcer (ZEU) is a rare, aggressive type of peptic ulcer caused by a gastrin‑producing tumor called a gastrinoma. Gastrin is a hormone that stimulates the stomach to release acid. When a gastrinoma secretes excessive gastrin, the stomach produces far more acid than normal, leading to ulcers that are typically multiple, larger, and resistant to standard ulcer therapy.

Who it affects: ZEU can occur at any age, but most patients are diagnosed between 40 and 70 years old. Both men and women are affected, with a slight male predominance (about 55 % male).

Prevalence: Gastrinomas are uncommon, accounting for less than 1 % of all gastric neoplasms. The annual incidence in the United States is ≈0.5–1 case per million people (≈1,600 new cases per year nationwide) <sup>CDC</sup>. About 20–30 % of gastrinomas are part of the hereditary syndrome Multiple Endocrine Neoplasia type 1 (MEN‑1).

Symptoms

Because the ulcers are caused by extreme acid production, the clinical picture often includes both classic ulcer symptoms and signs of hyperacidity.

Gastro‑intestinal symptoms

• Abdominal pain – typically a burning or gnawing pain that may worsen after meals (paradoxically, many patients experience relief with food because it buffers acid).
• Refractory ulcer disease – ulcers that do not heal despite proton‑pump inhibitor (PPI) therapy.
• Diarrhea – caused by acid inactivating pancreatic enzymes and damaging the intestinal mucosa; stools may be watery, sometimes greasy.
• Gastro‑esophageal reflux disease (GERD) – heartburn and sour taste due to excessive acid reflux.
• Nausea & vomiting – especially if the ulcer is obstructing the duodenum.

Systemic symptoms

• Weight loss – from malabsorption and chronic pain.
• Fatigue – secondary to anemia (occurs if ulcers bleed).
• Steatorrhea (fatty stools) – reflects pancreatic enzyme inactivation.

Signs that suggest a gastrinoma

• Elevated fasting serum gastrin > 1000 pg/mL (normal < 100 pg/mL).
• Positive secretin stimulation test (gastrin rises > 120 pg/mL after IV secretin).
• Multiple ulcerations seen on endoscopy, often beyond the duodenal bulb.

Causes and Risk Factors

The primary cause of Zollinger‑Ellison ulcer is a gastrinoma, which can be either sporadic or familial.

Gastrinoma origins

• Pancreatic gastrinomas – account for ~60 % of cases; arise in the pancreas or duodenal wall.
• Duodenal gastrinomas – ~30 % of cases; often small and difficult to detect.
• Extra‑pancreatic gastrinomas – rare; may occur in lymph nodes, liver, or metastatic sites.

Risk factors

• Multiple Endocrine Neoplasia type 1 (MEN‑1) – an inherited mutation in the  MEN1 gene; up to 25 % of patients with MEN‑1 develop gastrinomas.
• Family history of gastrinoma or MEN‑1.
• Chronic atrophic gastritis – long‑standing inflammation can raise gastrin levels, but does not cause true gastrinomas.
• Age > 40 years – incidence rises sharply after the fourth decade.

Diagnosis

Diagnosing ZEU requires a combination of biochemical testing, imaging, and endoscopic evaluation.

1. Biochemical confirmation

• Fasting serum gastrin – measured after an overnight fast; levels > 1000 pg/mL are highly suggestive of a gastrinoma, especially when gastric pH < 2.
• Secretin stimulation test – intravenous secretin normally suppresses gastrin; in gastrinomas it paradoxically stimulates a rise > 120 pg/mL.
• Gastric pH – a low pH (< 2) confirms hyperacidity.

2. Endoscopic assessment

• Upper endoscopy (EGD) – visualizes ulcer location, size, and number; biopsies are taken to rule out malignancy.
• Endoscopic ultrasound (EUS) – provides high‑resolution images of pancreatic and duodenal lesions and allows fine‑needle aspiration for pathology.

3. Imaging for tumor localization

• Multiphasic contrast‑enhanced CT scan – detects lesions > 5 mm and evaluates metastatic spread.
• Magnetic resonance imaging (MRI) with gadolinium – superior for liver metastases.
• Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT – highly sensitive for gastrinomas because most express somatostatin receptors.

4. Staging

The WHO/AJCC TNM system classifies gastrinomas as T1‑T4 (size/local invasion), N0‑N1 (lymph nodes), and M0‑M1 (distant metastasis). Staging guides treatment planning.

Treatment Options

Management combines control of acid hypersecretion, eradication or control of the tumor, and supportive care.

Acid‑control pharmacotherapy

• High‑dose proton‑pump inhibitors (PPIs) – e.g., omeprazole 60–80 mg/day or esomeprazole 40–80 mg/day; usually the cornerstone for symptom relief.
• Potassium‑competitive acid blockers (P‑CABs) – such as vonoprazan (available in some countries) offer rapid, profound acid suppression.
• Histamine‑2 receptor antagonists (H2RAs) – less effective alone but may be added for breakthrough symptoms.

Surgical approaches

• Curative resection – indicated for localized, non‑metastatic tumors.
  • Enucleation for small (< 2 cm) lesions without invasion.
  • Pancreaticoduodenectomy (Whipple) for larger pancreatic tumors or those near major ducts.
• Debulking surgery – removal of > 90 % of tumor burden in metastatic disease to reduce gastrin load.
• Liver metastasis management – hepatic resection, radiofrequency ablation, or transarterial chemoembolization (TACE) when feasible.

Medical therapies for tumor control

• Somatostatin analogues (octreotide, lanreotide) – bind somatostatin receptors, inhibit gastrin release, and can shrink tumors in up to 30 % of patients <sup>Cleveland Clinic</sup>.
• Targeted therapy – everolimus (mTOR inhibitor) has shown disease‑stabilization in advanced neuroendocrine tumors.
• Chemotherapy – streptozocin‑based regimens or temozolomide may be used for high‑grade or rapidly progressive disease.
• Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor‑positive cells; approved for metastatic neuroendocrine tumors.

Lifestyle & supportive measures

• Avoid NSAIDs, aspirin, and other ulcer‑aggravating medications.
• Limit alcohol and caffeine, which stimulate acid production.
• Small, low‑fat meals to reduce duodenal irritation.
• Supplement iron, vitamin B12, and fat‑soluble vitamins if malabsorption is present.

Living with Zollinger’s Ulcer

Long‑term management focuses on symptom control, monitoring for recurrence, and maintaining overall health.

Medication adherence

• Take PPIs exactly as prescribed—usually twice daily for the first few weeks, then taper to the lowest effective dose.
• Keep a medication diary; missing doses can lead to rapid symptom return.

Regular follow‑up

• Visit your gastroenterologist/endocrinologist every 3–6 months initially, then yearly if stable.
• Serum gastrin and fasting gastric pH should be checked at each visit.
• Imaging (CT/MRI or ^68Ga‑DOTATATE PET) every 12–24 months to detect recurrence or new metastases.

Nutrition tips

• Consume a balanced diet rich in lean protein, whole grains, and non‑citrus fruits.
• Include probiotic‑rich foods (yogurt, kefir) to support gut flora.
• Stay hydrated; aim for 2‑3 L of water daily unless fluid restriction is advised for other conditions.

Psychosocial support

• Join support groups for neuroendocrine tumor patients – sharing experiences reduces anxiety.
• Consider counseling if chronic pain or medication side‑effects affect mood.

Prevention

Because most gastrinomas are sporadic, primary prevention is limited. However, risk can be reduced in populations with known predisposition.

• Genetic counseling for families with MEN‑1 or known MEN1 mutations.
• Screening for at‑risk individuals – annual fasting gastrin measurement and abdominal imaging starting at age 20–30 for MEN‑1 carriers.
• Avoid chronic use of ulcer‑inducing drugs (e.g., NSAIDs) which can mask early symptoms and accelerate complications.
• Healthy lifestyle – smoking cessation, limited alcohol, and a balanced diet help maintain overall gastric health.

Complications

Untreated or poorly controlled ZEU can lead to serious health problems.

• Gastrointestinal bleeding – from ulcer erosion into vessels; may present as melena or hematemesis.
• Perforation – a hole in the stomach or duodenum causing acute abdomen and peritonitis.
• Obstruction – edema or scarring can block the duodenum, leading to vomiting and weight loss.
• Malabsorption & nutritional deficiencies – persistent acid inactivates pancreatic enzymes, causing steatorrhea, vitamin A/D/E/K deficiency, and osteoporosis.
• Metastatic disease – liver is the most common site; can cause hepatic dysfunction and hormone‑related symptoms.
• Refractory ulcer disease – ulcers that fail to heal increase the risk of carcinoma (though this is rare, occurring in < 1 % of cases).

When to Seek Emergency Care

---

**References**

• Mayo Clinic. “Zollinger‑Ellison syndrome.” mayoclinic.org
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Gastrinoma (Zollinger‑Ellison syndrome).” niddk.nih.gov
• World Health Organization. “Neuroendocrine tumours.” who.int
• Cleveland Clinic. “Somatostatin Analogs for Neuroendocrine Tumors.” clevelandclinic.org
• CDC. “Rare diseases statistics.” cdc.gov

```